BACKGROUND: Kohne et al. [Ann Oncol 2002;13:308-317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with different overall survival (OS). This model was applied to data from phase II/III trials of first-line bevacizumab plus 5-FU/LV with/without irinotecan (IFL). METHODS: Data on tumor sites, Eastern Cooperative Oncology Group performance status, alkaline phosphatase levels and white blood cell counts were used to classify patients into Kohne prognostic high-, intermediate- and low-risk groups. Median OS and progression-free survival (PFS) were calculated for patients receiving 5-FU/LV plus bevacizumab or placebo (n = 489) and IFL plus bevacizumab or placebo (n = 812). RESULTS:Median OS was longer in 5-FU/LV/bevacizumab (11.2-22.6 months) than in the 5-FU/LV/placebo (5.7-17.5 months), and in the IFL/bevacizumab arm (14.3-22.5 months) than in the IFL/placebo arm (8.4-17.9 months) across the Kohne high-, intermediate- and low-risk groups. The addition of bevacizumab also extended median PFS across the Kohne risk groups compared with placebo. CONCLUSIONS:Bevacizumab improves OS and PFS across the Kohne risk classification in patients with metastatic CRC. The Kohne model can be extended to patients treated with 5-FU/LV/bevacizumab, IFL and IFL/bevacizumab and to PFS data. Copyright 2008 S. Karger AG, Basel.
RCT Entities:
BACKGROUND: Kohne et al. [Ann Oncol 2002;13:308-317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with different overall survival (OS). This model was applied to data from phase II/III trials of first-line bevacizumab plus 5-FU/LV with/without irinotecan (IFL). METHODS: Data on tumor sites, Eastern Cooperative Oncology Group performance status, alkaline phosphatase levels and white blood cell counts were used to classify patients into Kohne prognostic high-, intermediate- and low-risk groups. Median OS and progression-free survival (PFS) were calculated for patients receiving 5-FU/LV plus bevacizumab or placebo (n = 489) and IFL plus bevacizumab or placebo (n = 812). RESULTS: Median OS was longer in 5-FU/LV/bevacizumab (11.2-22.6 months) than in the 5-FU/LV/placebo (5.7-17.5 months), and in the IFL/bevacizumab arm (14.3-22.5 months) than in the IFL/placebo arm (8.4-17.9 months) across the Kohne high-, intermediate- and low-risk groups. The addition of bevacizumab also extended median PFS across the Kohne risk groups compared with placebo. CONCLUSIONS:Bevacizumab improves OS and PFS across the Kohne risk classification in patients with metastatic CRC. The Kohne model can be extended to patients treated with 5-FU/LV/bevacizumab, IFL and IFL/bevacizumab and to PFS data. Copyright 2008 S. Karger AG, Basel.
Authors: Pinar Karaca-Mandic; Jeffrey S McCullough; Mustaqeem A Siddiqui; Holly Van Houten; Nilay D Shah Journal: J Oncol Pract Date: 2011-05 Impact factor: 3.840
Authors: Nikol Snoeren; Emile E Voest; Andre M Bergman; Otilia Dalesio; Henk M Verheul; Rob A E M Tollenaar; Joost R M van der Sijp; Sander B Schouten; Inne H M Borel Rinkes; R van Hillegersberg Journal: BMC Cancer Date: 2010-10-11 Impact factor: 4.430
Authors: Kaitlyn K H Goey; Sjoerd G Elias; Axel Hinke; Martijn G H van Oijen; Cornelis J A Punt; Susanna Hegewisch-Becker; Dirk Arnold; Miriam Koopman Journal: Br J Cancer Date: 2017-11-09 Impact factor: 7.640
Authors: Reem D Mahmood; Danielle Shaw; Tine Descamps; Cong Zhou; Robert D Morgan; Saifee Mullamitha; Mark Saunders; Nerissa Mescallado; Alison Backen; Karen Morris; Ross A Little; Susan Cheung; Yvonne Watson; James P B O'Connor; Alan Jackson; Geoff J M Parker; Caroline Dive; Gordon C Jayson Journal: BMC Cancer Date: 2021-04-01 Impact factor: 4.430